论文部分内容阅读
喹啉噻唑(Quinethazone)是属于磺酰胺系的一个新利尿药,此药能使尿钠和尿钾的排出增加。作者以生物检定的方法,在一组28个没有肾脏或心血管疾病的佳院病人中,限制饮食中钠盐含量到一克,收集病人24小时排出的尿,测定尿中的电解质。当尿钠排出下降到将近是吸收进去的90％时,就给予病人口服喹啉噻唑,继续收集病人24小时排出的尿,再行测定尿中的电解质。结果发现,给予200毫克和300毫克喹啉噻唑的病人,平均24小时尿钠排出比对照组各增加98毫克当量(P<0.001)和100毫克当量(P<0.001),尿钾排出比尿钠少,
Quinethazone is a new diuretic belonging to the sulfonamide family that increases urinary sodium and urinary potassium excretion. In a bioassay approach, in a group of 28 hospitalized patients without renal or cardiovascular disease, the authors limited the sodium content in the diet to one gram. Urine discharged from the patient for 24 hours was collected and urine electrolytes were measured. When urinary sodium excretion drops to approximately 90% of the absorbed, the patient is given oral quinoline thiazole and the patient continues to collect the urine excreted for 24 hours. The urine electrolytes are then measured. The results showed that patients given 200 mg and 300 mg quinolizidine had an average 24-hour urinary sodium excretion of 98 milliequivalents (P <0.001) and 100 milliequivalents (P <0.001), respectively, more than the control group less,